mindpeak.aiCrawled Nov 4, 2026
De-risk clinical trials with AI-powered biomarker discovery, precision patient selection, and global deployment. End-to-end platform for biopharma.
At ESMO2025, Mindpeak and AstraZeneca delivered new evidence on how AI can advance precision oncology – sharing results from a multinational study validating AI-assisted HER2 immunohistochemistry (IHC) scoring across 12 academic centres and more than 1,000 breast cancer cases.
Using challenging validation data from three institutions and four scanners, ROI scoring with the support of our Al. PD-L1 quantifier showed high agreement with pathologists, while significantly reducing assessment time.
The emergence of novel therapies targeting low and ultralow HER2 expression in breast cancer stresses the need for accurate, reproducible HER2 immunohistochemistry (IHC) assessment.
New HER2-low and -ultralow breast cancer treatments require precise HER2 IHC scoring, but variability in staining and subjective judgment create challenges. AI tools may improve accuracy, though real-world data—especially for ultralow cases—remains limited.
Partnership combines Mindpeak’s PhenoScout AI image analysis with Revolune’s multiplex IF kits to streamline the path from tissue staining to spatial discovery.
Mindpeak sets standards: Together with a small group of entrepreneurs, experts and scientists as well as the Deutsche Institute für Normung e.V. DIN, Mindpeak is developing the future industry standards for deep learning image recognition systems.
Join Mindpeak in building AI that enables better cancer diagnostics. Help extend and improve lives through effective treatment for every patient.
In a first of its kind comparative study, Mindpeak's CE-marked HER2 AI for breast cancer diagnosis was compared to three other commercial AIs (e.g. Visiopharm).
Mindpeak transforms tissue into high-dimensional data, enabling the discovery of AI-driven biomarkers that guide targeted therapies and power precision medicine.
Privacy policy of MindPeak GmbH
